Description
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies.
Cat.No
A774
Name
Tregalizumab
Chemical Properties
CAS
1207446-68-1
Synonyms
Tregalizumab;Research Grade Tregalizumab;Research Grade Tregalizumab;Research Grade Tregalizumab;Research Grade Tregalizumab;Research Grade Tregalizumab;Tregalizumab (anti-CD4);Tregalizumab (anti-CD4);Tregalizumab (anti-CD4);Tregalizumab (anti-CD4);Tregalizumab (anti-CD4), BT-061
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Tregalizumab |CAS1207446-68-1|DC Chemicals
Peptide mapping
Tregalizumab |CAS1207446-68-1|DC Chemicals
N-terminal sequence
Tregalizumab |CAS1207446-68-1|DC Chemicals
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131Fax: +86-21-61642470Email:
Website:
